Respiratorius AB Logo

Respiratorius AB

RESP | SPGR

Overview

Corporate Details

ISIN(s):
SE0004550192 (+2 more)
LEI:
5493001YRVZ5XYFEE615
Country:
Sweden
Address:
Scheeletorget 1, 223 81 Lund
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Respiratorius AB is a research-based pharmaceutical company focused on the development of innovative drug candidates. The company's primary focus is on oncology, specifically creating new treatments for aggressive forms of cancer such as diffuse large B-cell lymphoma (DLBCL). Its lead strategy involves developing a drug candidate intended as a pretreatment to enhance the efficacy of current standard therapies. Founded in 1999 as a spin-off from Lund University, Respiratorius leverages a team with extensive experience in clinical development, commercialization of research, and pharmaceutical business development. While historically involved in developing drugs for COPD and asthma, its current pipeline is centered on cancer.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Respiratorius AB. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Respiratorius AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Respiratorius AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-12-06 Johan Drott Other Buy 1,120 N/A

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN